HUP0002250A3 - Gelatine encapsulated solution dosage forms of sertraline - Google Patents

Gelatine encapsulated solution dosage forms of sertraline

Info

Publication number
HUP0002250A3
HUP0002250A3 HU0002250A HUP0002250A HUP0002250A3 HU P0002250 A3 HUP0002250 A3 HU P0002250A3 HU 0002250 A HU0002250 A HU 0002250A HU P0002250 A HUP0002250 A HU P0002250A HU P0002250 A3 HUP0002250 A3 HU P0002250A3
Authority
HU
Hungary
Prior art keywords
sertraline
dosage forms
solution dosage
encapsulated solution
gelatine encapsulated
Prior art date
Application number
HU0002250A
Other languages
English (en)
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=21971076&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HUP0002250(A3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of HUP0002250A2 publication Critical patent/HUP0002250A2/hu
Publication of HUP0002250A3 publication Critical patent/HUP0002250A3/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Addiction (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
HU0002250A 1997-07-01 1998-06-16 Gelatine encapsulated solution dosage forms of sertraline HUP0002250A3 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US5140197P 1997-07-01 1997-07-01

Publications (2)

Publication Number Publication Date
HUP0002250A2 HUP0002250A2 (hu) 2000-12-28
HUP0002250A3 true HUP0002250A3 (en) 2001-01-29

Family

ID=21971076

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0002250A HUP0002250A3 (en) 1997-07-01 1998-06-16 Gelatine encapsulated solution dosage forms of sertraline

Country Status (40)

Country Link
EP (1) EP0980241B1 (hu)
JP (1) JP3585245B2 (hu)
KR (1) KR100371730B1 (hu)
CN (1) CN1261792A (hu)
AP (1) AP945A (hu)
AR (1) AR015916A1 (hu)
AT (1) ATE256457T1 (hu)
AU (1) AU724635B2 (hu)
BG (1) BG103917A (hu)
BR (1) BR9809712A (hu)
CA (1) CA2290973C (hu)
CO (1) CO4940405A1 (hu)
DE (1) DE69820608T2 (hu)
DK (1) DK0980241T3 (hu)
DZ (1) DZ2544A1 (hu)
EA (1) EA001905B1 (hu)
ES (1) ES2210760T3 (hu)
GT (1) GT199800090A (hu)
HR (1) HRP980378B1 (hu)
HU (1) HUP0002250A3 (hu)
ID (1) ID24673A (hu)
IL (1) IL133075A0 (hu)
IS (1) IS5266A (hu)
MA (1) MA24586A1 (hu)
MY (1) MY119728A (hu)
NO (1) NO996492L (hu)
NZ (1) NZ501252A (hu)
OA (1) OA11246A (hu)
PA (1) PA8454001A1 (hu)
PE (1) PE97299A1 (hu)
PL (1) PL337807A1 (hu)
PT (1) PT980241E (hu)
SK (1) SK282914B6 (hu)
TN (1) TNSN98123A1 (hu)
TR (1) TR199903282T2 (hu)
TW (1) TW382597B (hu)
UA (1) UA68350C2 (hu)
UY (1) UY25070A1 (hu)
WO (1) WO1999001113A1 (hu)
ZA (1) ZA985709B (hu)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6727283B2 (en) 1998-10-13 2004-04-27 Pfizer Inc. Sertraline oral concentrate
EE04868B1 (et) * 1998-10-13 2007-08-15 Pfizer Products Inc. Farmatseutiline kompositsioon, mis sisaldab vett mittesisaldavat, vedelat kontsentraati oraalseks manustamiseks, mis sisaldab sertraliini v?i selle farmatseutiliselt vastuv?etava soola kogust ning hte v?i rohkemat vett mittesisaldavat farmatseutilis
UA75580C2 (uk) 1999-09-03 2006-05-15 Апбі Холдінгс, Ллк Застосування дапоксетину або його фармацевтично прийнятної солі в лікарському засобі для лікування розладу статевої функції та промисловий виріб для його застосування
CA2420535A1 (en) 2000-08-30 2002-03-07 Mary Tanya Am Ende Sustained release formulations for growth hormone secretagogues
EP1375659A1 (en) * 2002-06-18 2004-01-02 Laboratorio di Diagnostica Moleculare Soluble capsules containing stock mixtures for easy preparation of chemical or biological solutions
US20040142040A1 (en) * 2002-10-31 2004-07-22 Dong Liang C. Formulation and dosage form providing increased bioavailability of hydrophobic drugs
WO2016020936A2 (en) * 2014-07-21 2016-02-11 Patel Jayendrakumar Dasharathlal A novel oral gastroretentive pharmaceutical dosage form
CN108014087A (zh) * 2017-12-27 2018-05-11 江苏联环药业股份有限公司 一种盐酸舍曲林胶囊的制备方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2197554A1 (en) * 1994-09-19 1996-03-28 The Du Pont Merck Pharmaceutical Company Combination of an opioid antagonist and a selective serotonin reuptake inhibitor for treatment of alcoholism and alcohol dependence
DK0768083T3 (da) * 1995-07-17 2003-06-23 Pfizer Anvendelse af sertralin til at behandle patienter med post myocardisk infarkt

Also Published As

Publication number Publication date
HRP980378B1 (en) 2001-12-31
OA11246A (en) 2002-11-19
ID24673A (id) 2000-07-27
DE69820608D1 (de) 2004-01-29
EA199900963A1 (ru) 2000-08-28
PT980241E (pt) 2004-03-31
CA2290973C (en) 2003-06-17
JP2000512316A (ja) 2000-09-19
TNSN98123A1 (fr) 2005-03-15
NZ501252A (en) 2004-11-26
CO4940405A1 (es) 2000-07-24
EP0980241B1 (en) 2003-12-17
JP3585245B2 (ja) 2004-11-04
CN1261792A (zh) 2000-08-02
HUP0002250A2 (hu) 2000-12-28
HRP980378A2 (en) 1999-04-30
TR199903282T2 (xx) 2000-08-21
EA001905B1 (ru) 2001-10-22
BG103917A (bg) 2000-07-31
KR100371730B1 (ko) 2003-02-07
SK282914B6 (sk) 2003-01-09
ZA985709B (en) 2000-01-10
AU7545098A (en) 1999-01-25
NO996492L (no) 2000-02-29
TW382597B (en) 2000-02-21
WO1999001113A1 (en) 1999-01-14
MA24586A1 (fr) 1998-12-31
IS5266A (is) 1999-11-23
DE69820608T2 (de) 2004-12-23
KR20010013588A (ko) 2001-02-26
EP0980241A1 (en) 2000-02-23
UA68350C2 (en) 2004-08-16
CA2290973A1 (en) 1999-01-14
PA8454001A1 (es) 2000-05-24
AR015916A1 (es) 2001-05-30
DZ2544A1 (fr) 2003-02-08
DK0980241T3 (da) 2004-04-05
SK180599A3 (en) 2001-01-18
BR9809712A (pt) 2000-07-11
PL337807A1 (en) 2000-09-11
AP945A (en) 2001-02-28
AP9801279A0 (en) 1998-06-30
ATE256457T1 (de) 2004-01-15
PE97299A1 (es) 1999-10-13
ES2210760T3 (es) 2004-07-01
UY25070A1 (es) 2000-12-29
AU724635B2 (en) 2000-09-28
NO996492D0 (no) 1999-12-27
MY119728A (en) 2005-07-29
IL133075A0 (en) 2001-03-19
GT199800090A (es) 1999-12-21

Similar Documents

Publication Publication Date Title
HUP0002296A3 (en) Sertraline salts and sustained-release dosage forms of sertraline
SG70562A1 (en) Potentiation of drug response
DE19681727T1 (de) Kapseln/Teilchen enthaltende Shampoo-Zusammensetzung
HUP0105107A3 (en) Fast dispersing dosage forms free of gelatin
HUP0000759A3 (en) Dosage forms comprising separate portions of r- and s-enantiomers
ZA9511034B (en) Soft gelatin pharmaceutical dosage form
ZA975767B (en) Multiphase soft gelatin dosage form
AP9801278A0 (en) Delayed-release dosage forms of sertraline
IL133075A0 (en) Gelatine encapsulated solution dosage forms of sertraline
SI0980241T1 (en) Gelatine encapsulated solution dosage forms of sertraline
DE9414607U1 (de) Parfümkapsel
ZA948357B (en) Potentiation of drug response
ZA985707B (en) Sertraline salts and sustained-release dosage forms of sertraline.
GB9703750D0 (en) Treatment of haemorrhoids
HU9701917D0 (en) New compound of medicinal activity
AUPM590295A0 (en) Manufacture of pharmaceutical dosage forms
TW313845U (en) Improved structure of pacifier
BR9504107A (pt) Encapsulamento de peças anatômicas
TW398283U (en) Improved structure of mask
TW314782U (en) Improved structure of mask
ZA956361B (en) Dosing of animals